翻訳と辞書 |
David H. Kirn : ウィキペディア英語版 | David H. Kirn David H. Kirn is an American entrepreneur and scientist. He is co-Founder, co-Chairman and CEO of 4D Molecular Therapeutics (4DMT, which he founded with David Schaffer in 2013), a biotechnology working on adeno-associated virus gene therapy vectors.〔Yan, Wudan. "Starting up and Spinning Out: The Changing Nature of Partnerships between Pharma and Academia." Nature Medicine Nat Med 21.9 (2015): 968-71. Web.〕〔 Mai, Don. "About the Schaffer Lab." Schaffer Research Group. University of California Berkeley, n.d. Web. 27 July 2015. .〕 Prior to 4DMT, Kirn was Founder and CEO of Jennerex (2003-2013) and Vice President of Clinical Research at Onyx Pharmaceuticals (1994-2000).〔"David H. Kirn M.D.: Executive Profile & Biography." Bloomberg.com. Bloomberg, n.d. Web. 27 July 2015. http://www.bloomberg.com/research/stocks/private/person.asp?personId=38652599&privcapId=29846313&previousCapId=257084190&previousTitle=Avidity+NanoMedicines+LLC.〕〔"David Kirn, MD." CALBIO 2015. CALBIO, n.d. Web. .〕〔Holtz, Andrew. "To Build a Killing Machine." The Scientist. LabX Media Group, 1 May 2007. Web. .〕 Kirn has held academic positions at the University of California, San Francisco Medical School; the University of Oxford; and was chief medical resident at Harvard Medical School. His published work on oncolytic adenoviruses includes Onyx-015 and has appeared in ''Nature''. He has co-authored over 100 publications in peer-reviewed journals.〔"Publications Authored by David H. Kirn." PUBFACTS. PUBFACTS, n.d. Web. 27 July 2015. http://www.pubfacts.com/author/David+H+Kirn.〕〔"David H Kirn." Microsoft Academic Search. Microsoft, n.d. Web. 3 Aug. 2015. .〕 == References ==
抄文引用元・出典: フリー百科事典『 ウィキペディア(Wikipedia)』 ■ウィキペディアで「David H. Kirn」の詳細全文を読む
スポンサード リンク
翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|